A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism

(2019) Karen J. Parker et al.   Science Translational Medicine

Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial

(2018) Hidenori Yamasue et al.   MOLECULAR PSYCHIATRY

A Review of Oxytocin and Arginine-Vasopressin Receptors and Their Modulation of Autism Spectrum Disorder

(2018) Ilaria Cataldo et al.   Frontiers in Molecular Neuroscience

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension

(2017) Michael G. Aman et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results

(2017) Eriene A Youssef et al.   NEUROPSYCHOPHARMACOLOGY

Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism

(2017) Karen J. Parker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adults with Autism Spectrum Disorders

(2017) Patricia Howlin et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

Epidemiology of autism in adults across age groups and ability levels

(2016) Traolach S. Brugha et al.   BRITISH JOURNAL OF PSYCHIATRY

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

(2016) Daniel Umbricht et al.   NEUROPSYCHOPHARMACOLOGY

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial

(2016) Jeremy Veenstra-VanderWeele et al.   NEUROPSYCHOPHARMACOLOGY

Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

(2016) Elizabeth Berry-Kravis et al.   Science Translational Medicine

Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial

(2016) H Kosaka et al.   Translational Psychiatry

Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism

(2015) Takamitsu Watanabe et al.   BRAIN

Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems

(2015) Traolach S. Brugha et al.   INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH

Discovery of Highly Selective Brain-Penetrant Vasopressin 1a Antagonists for the Potential Treatment of Autism via a Chemogenomic and Scaffold Hopping Approach

(2015) Hasane Ratni et al.   JOURNAL OF MEDICINAL CHEMISTRY

The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial

(2015) C J Yatawara et al.   MOLECULAR PSYCHIATRY

Can oxytocin treat autism?

(2015) L. J. Young et al.   SCIENCE

The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial

(2014) Adam J. Guastella et al.   JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY

Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism

(2013) Jakob Christensen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Oxytocin and vasopressin: Social neuropeptides with complex neuromodulatory functions

(2013) E. E. Benarroch   NEUROLOGY

Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction

(2013) James K. Rilling et al.   PSYCHONEUROENDOCRINOLOGY

Mitigation of Sociocommunicational Deficits of Autism Through Oxytocin-Induced Recovery of Medial Prefrontal Activity

(2013) Takamitsu Watanabe et al.   JAMA Psychiatry

Neuromodulation by Oxytocin and Vasopressin

(2012) Ron Stoop   NEURON

Gestational Valproate Alters BOLD Activation in Response to Complex Social and Primary Sensory Stimuli

(2012) Ada C. Felix-Ortiz et al.   PLoS One

Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial

(2012) Evdokia Anagnostou et al.   Molecular Autism

The contributions of oxytocin and vasopressin pathway genes to human behavior

(2011) Richard P. Ebstein et al.   HORMONES AND BEHAVIOR

The regulation of social recognition, social communication and aggression: Vasopressin in the social behavior neural network

(2011) H. Elliott Albers   HORMONES AND BEHAVIOR

Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men

(2011) James K. Rilling et al.   PSYCHONEUROENDOCRINOLOGY

Intranasal Arginine Vasopressin Enhances the Encoding of Happy and Angry Faces in Humans

(2010) Adam J. Guastella et al.   BIOLOGICAL PSYCHIATRY

The Challenge of Translation in Social Neuroscience: A Review of Oxytocin, Vasopressin, and Affiliative Behavior

(2010) Thomas R. Insel   NEURON

Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans

(2008) A Meyer-Lindenberg et al.   MOLECULAR PSYCHIATRY